VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · IEX Real-Time Price · USD
2.530
+0.010 (0.40%)
At close: May 1, 2024, 4:00 PM
2.990
+0.460 (18.18%)
After-hours: May 1, 2024, 5:00 PM EDT
VYNE Therapeutics Revenue
In the year 2023, VYNE Therapeutics had annual revenue of $424.00K, a decrease of -11.11%. Revenue in the quarter ending December 31, 2023 was $76.00K with 1,166.67% year-over-year growth.
Revenue (ttm)
$424.00K
Revenue Growth
-11.11%
P/S Ratio
84.13
Revenue / Employee
$42,400
Employees
10
Market Cap
35.67M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 424.00K | -53.00K | -11.11% |
Dec 31, 2022 | 477.00K | -454.00K | -48.76% |
Dec 31, 2021 | 931.00K | -20.06M | -95.57% |
Dec 31, 2020 | 20.99M | 20.55M | 4,638.83% |
Dec 31, 2019 | 443.00K | -3.15M | -87.68% |
Dec 31, 2018 | 3.60M | -987.00K | -21.54% |
Dec 31, 2017 | 4.58M | 3.91M | 579.82% |
Dec 31, 2016 | 674.00K | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
LENSAR | 42.16M |
Precision Optics Corporation | 19.22M |
electroCore | 16.03M |
Co-Diagnostics | 6.81M |
Evogene | 5.64M |
Marker Therapeutics | 3.31M |
IGC Pharma | 1.22M |
VYNE News
- 16 hours ago - VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting - GlobeNewsWire
- 6 weeks ago - VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference - GlobeNewsWire
- 2 months ago - VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium - GlobeNewsWire
- 2 months ago - VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference - GlobeNewsWire
- 3 months ago - Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI) - Benzinga
- 4 months ago - VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo - GlobeNewsWire
- 4 months ago - VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors - GlobeNewsWire